[New salicylic acid derivatives in the treatment of inflammatory intestinal diseases].
Drug therapy for inflammatory bowel disease was limited for many years to sulfasalazine and some corticosteroids. Since the discovery that 5-aminosalicylic acid (5-ASA) is the active moiety of sulphasalazine in the treatment of chronic inflammatory bowel disease, several new drugs have been developed. These consist either of slow- or delayed-release formulations of plaint 5-ASA (mesalazin) or sulpha-free azo-compounds of 5-ASA. The varying bioavailabilities of the different formulations and compounds make it possible to use them alternatively in different clinical situations. A review of the literature is given and suggestions as to how the new drugs can be used in different diseases.